Role of Spevigo® (spesolimab-sbzo) Injection in the Treatment of Generalized Pustular Psoriasis

Listen

0:00 / 0:00

This Clinical Brief is supported by Boehringer Ingelheim.

This article provides an overview of generalized pustular psoriasis (GPP) and its clinical and economic impact, and reviews findings of Effisayil^® 2, the first trial to study subcutaneous Spevigo^® (spesolimab-sbzo) in patients with GPP when not experiencing a flare.

Stay ahead of policy, cost, and value—subscribe to AJMC for expert insights at the intersection of clinical care and health economics.

Role of Spevigo® (spesolimab-sbzo) Injection in the Treatment of Generalized Pustular Psoriasis

Trending on AJMC

FDA Panel Backs 6 Peptides for Compounding

FAQs: Cyclospora Recovery, Treatment, and Outbreak Prevention Strategies

Teclistamab-Talquetamab Combo Cuts Myeloma Progression Risk by 89%

Study Shows Potential for Low-Dose CAR T, With Implications for Increased Access